Report overview
hematologic cancer. Cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are leukemia, lymphoma, and multiple myeloma. Also called blood cancer.
This report aims to provide a comprehensive presentation of the global market for Hematological Cancers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hematological Cancers. This report contains market size and forecasts of Hematological Cancers in global, including the following market information:
Global Hematological Cancers Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Hematological Cancers market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Pharmacological Therapies Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hematological Cancers include Karyopharm Therapeutics, Johnson & Johnson, Roche Diagnostics A/S, AbbVie, Novartis, Kite Pharma, Celgene Corporation, Abbott Laboratories and Beckman Coulter, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hematological Cancers companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hematological Cancers Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Hematological Cancers Market Segment Percentages, by Type, 2022 (%)
Pharmacological Therapies
Stem Cell Transplantation
Surgery and Radiation Therapy
Anemia Treatment
Thrombosis Treatment
Neutopenia Treatment
Symptomatic treatment
Global Hematological Cancers Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Hematological Cancers Market Segment Percentages, by Application, 2022 (%)
Epidemiology
Pathophysiology of Leukemic Stem Cells
Kidney Diseases
Genetic Diseases
Other Diseases
Global Hematological Cancers Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Hematological Cancers Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hematological Cancers revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hematological Cancers revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Karyopharm Therapeutics
Johnson & Johnson
Roche Diagnostics A/S
AbbVie
Novartis
Kite Pharma
Celgene Corporation
Abbott Laboratories
Beckman Coulter
HemoCue AB
C. R. Bard
Siemens AG
Sysmex
Mindray Medical International Limited
Bio-Rad Laboratories
The Medicine Company
Pharmacyclics
Horiba
DiagnoCure Inc.
Astellas Pharma US
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hematological Cancers, market overview.
Chapter 2: Global Hematological Cancers market size in revenue.
Chapter 3: Detailed analysis of Hematological Cancers company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hematological Cancers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
